Brief: Biomed Lublin Informs Of Company's Anti-Covid Immunoglobulin Therapy Results

Synthaverse SA

29/11/2021 07:51

Nov 29 (Reuters) - Biomed Lublin Wytwornia Surowic i
Szczepionek SA  BML.WA :
    * INFORMS OF COMPANY'S ANTI-COVID IMMUNOGLOBULIN THERAPY
RESULTS
    * COMPANY'S ANTI-COVID IMMUNOGLOBULIN THERAPY CLINICAL TEST
PHASE
HAS FINISHED
    * COMPANY IS CAPABLE OF PRODUCING ANTI-COVID IMMUNOGLOBULIN,
BUT
THERAPY ITSELF DOES NOT HAVE SIGNIFICANT IMPACT ON PATIENT'S
RECOVERY
    * COMPANY'S ANTI-COVID IMMUNOGLOBULIN THERAPY PROVED TO BE
BENEFICIAL FOR PATIENTS IN EARLY-STAGE OF INFECTION
    * COMPANY'S IS  READY TO CONTINUE WORKS AS PART OF
CONSORTIUM OR
IN DIFFERENT FORM AS TECHNOLOGICAL PROVIDER IN ANTI-COVID
IMMUNOGLOBULIN THERAPY PROJECT

Source text for Eikon:  ID:nEM36LMpma 
Further company coverage:  BML.WA 

 (Reporting by Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))